Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment
5 days ago
- #systemic lupus erythematosus
- #biologics
- #early diagnosis
- Progression from at-risk state to clinical and severe systemic lupus erythematosus (SLE) involves molecular dysregulations.
- Transcriptomic changes were explored during progression from preclinical to clinical and advanced SLE.
- At-risk individuals showed deregulated metabolic, cytokine signalling, haematologic, and stress-response pathways.
- Progressors exhibited heightened interferon (IFN)-alpha/gamma and inflammatory cytokine activity.
- A 17-gene susceptibility signature predicted transition to SLE with an area under the curve of 0.80.
- Stepwise upregulation of IFN-α/γ, haem metabolism, and oxidative phosphorylation pathways was observed.
- SLE susceptibility and progression signatures demonstrated potential reversibility by biologics like anifrolumab and belimumab.
- Blood molecular profiling may aid risk stratification and early biologic intervention.